3 months ago
1
The Central Drugs Standard Control Organization (CDSCO) has issued an advisory to pharmaceutical manufacturers, importers, and selling authorisation holders to guarantee strict compliance with the provisions of the Drugs and Cosmetics Act, 1940 and Rules, 1945 successful the promotion and selling of medicine medicines, peculiarly GLP-1 receptor agonists and akin drugs indicated for obesity and metabolic disorders.
The advisory highlights interest regarding definite promotional activities, including illness consciousness campaigns and integer outreach, that whitethorn indirectly beforehand prescription-only medicines to the public. The CDSCO has clarified that specified drugs indispensable beryllium prescribed lone by registered aesculapian practitioners successful accordance with approved indications and conditions of selling authorisation.
The regulator has reiterated that immoderate nonstop oregon indirect advertisement of medicine medicines to the nationalist is strictly prohibited, including promotional activities connected print, electronic, digital, oregon societal media platforms.
Activities that exaggerate therapeutic claims, warrant weight-loss outcomes, oregon undermine the value of manner modifications specified arsenic fare and carnal enactment volition beryllium treated arsenic misleading promotion.
The CDSCO has advised each acrophobic stakeholders to strictly adhere to regulatory and ethical selling standards.
Firms person besides been directed to guarantee due prescribing information, support user grievance mechanisms, and taxable broad hazard absorption plans to guarantee continued information monitoring.
The advisory emphasises that obesity is simply a chronic metabolic information requiring broad management, including manner interventions, and pharmaceutical therapy should not beryllium projected successful a mode that undermines broader nationalist wellness initiatives.
